We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
- Three agents with the potential to reach the market this year for hemophilia A and B, primary biliary cholangitis, and post-traumatic stress disorder (PTSD).
- Other significant treatments expected in the next few years, including gene therapies and biosimilars in the pipeline.
- A review of novel drug approvals in 2023.
- A spotlight on the nomenclature changes for nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), and an overview of atopic dermatitis treatment.
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.
You may also be interested in:
2024 Legislative Forecast
Q1 2024 CarelonRx DrugInsights Update
Our Evidence-Based Formulary Development Process
